Available Technologies

Disposable Filtration System for Cytology Creates Cell Blocks for Fine Needle Aspiration (FNA) Biopsy

2958 — This cell block preparation device biopsy system, called XCellent, is a disposable filtration system for fine needle aspirations (FNAs), fluids, and small biopsies  that maximizes cell collection from minute tissue samples. XCellent can be used in cytology laboratories that process cell blocks or small biopsies,  by clinicians who perform FNAs, and by research laboratories that seek to isolate cells from a liquid component.  In fine-needle aspiration, the entire FNA sample (<1ml) consist...

Hair-Loss Treatment with Hair-Loss Gene Promotes New Hair Growth, Regulates Male-Pattern Baldness and Graying Hair

2419 — This hair-loss gene technology represents a non-surgical hair-loss treatment and a potential drug target for preventing further hair loss. The discovery of the APCDD1 gene, which causes hair loss, has potential for future male-pattern baldness treatments, and for regulating male and female hair growth, density of hair, and hair graying.  Hair loss affects millions of people worldwide. Hair loss can be an emotionally devastating skin disease, as measured by impact on quality of life. Two...

Cancer therapy inhibits metastasis, spread of cancer

1708 — As the incidence of cancer continues to rise, additional therapeutic technologies are needed more than ever. Current adjuvant therapies inject hormones, antibodies, or other peptides into the patient; however, these therapeutics are expensive to manufacture and do not always prevent metastasis (the spread of the cancer to other parts of the body.) Novel and more cost-effective classes of cancer therapeutic strategies are critical for improved prevention of metastasis that results in the ...

Prostate cancer blood test

647 — The measurement of serum levels of Prostate-Specific Antigen (PSA) or Prostate-Specific Membrane Antigen (PSM) is currently used in the early detection of prostate cancer. Although more effective at detecting prostate cancer than physical examination, PSA screening is inadequate because elevated levels of the antigen do not necessarily indicate the presence of prostate cancer and the test therefore may produce false positives. The technology is a sensitive diagnostic blood test fo...

Cancer tumor treatment with radiation

599 — “Name of the inventor: Judah Z. Weinberger Apparatus for applying radiation using controller: A radiation therapy apparatus and method for applying radiation to a patient in synchronism with one of several states of a cardiac cycle and one of several states of a respiratory cycle of the patient are described. Radiation applied using controlle that monitors heart and lung function: An electrocardiograph and a respiratory monitor are operatively connected to the patient. A controller r...

Detecting and Treating Prostate Cancer

proxyfisher4 — “Name of the inventor: Paul Fisher Prostate Cancer Detection by Determining Presence of Isolated Polypeptide Compositions and methods for the detection and therapy of prostate cancer are described. Diagnostic Kit for Detecting and Monitoring Progress of Prostate Cancer The isolated polypeptide comprises an immunologically active portion of a tumor-associated protein or a variant. A vaccine comprises an antigen presenting cell that expresses a polypeptide and a non-specific immune response e...

Free Radicals in Cancer Treatment

1231 — “Name of the inventor: Paul Fisher Treating Cancer By Generating Melanoma Differentiation Associated Gene and Free Radicals in Cancer Cells: An effective amount of MDA-7 is generated by administering MDA-7 nucleic acid, MDA-7 protein or their functional equivalents, or by up-regulation of the endogenous MDA-7 gene or stabilization of the MDA-7 mRNA in the cancer cell. Free radicals are generated in the cancer cell by exposing the cancer cell to an effective amount of ionizing radiation...

Mouse stem cells for cancer drug screening

585 — Rad9 was previously identified by Dr. Lieberman ( ) and promotes cell survival through the regulation of DNA repair and the activation of cell cycle checkpoints induced by DNA damage. Mouse embryonic stem (ES) cells with a targeted deletion of Mrad9, the mouse ortholog of the gene, were created to evaluate the function of the protein in mammals. Mrad9-/- ES cells and Mrad9+/- mice are both available for use in cancer research. Both the mouse and cell lines, with deficient response...

Nucleic acid molecule biomarkers for cancer studies

601 — “Name of the inventor: Beth C. Levine Production, recovery, and purification of wild-type human beclin using a host-vector system: An isolated nucleic acid which encodes a wild-type human beclin and a mutant human beclin is described. A method of producing a wild-type human beclin using a host-vector system and method of recovery and purification of the wild-type human beclin are disclosed. Nucleic acid encoding a wild-type human beclin for cancer research: The isolated nucleic acid e...

Gene therapy for the treatment of cancer

629 — “Name of the inventor: Paul Fisher Tumor supressor gene causes cancer cell apoptosis: An inducible PEG-3 regulatory region (promoter) and a gene encoding a toxic product that is capable of causing or may be induced to cause apoptosis/inhibition of cancer cell growth are described. Viral vectors targeted to kill cancer cells: A tumor suppressor gene is included in the vector that encodes viral replication proteins that are toxic to cells and may cause the expression of specific antig...

Cancer Treatment with Notch-based Fusion Proteins

1530 — Recent progress in the treatment of cancer has focused on the development of biologic drugs that target specific molecular pathways. Successful biologic drugs (i.e. Herceptin, Avastin, etc.) focus particularly on cellular processes that are dysfunctionally regulated in cancers, such as excessive growth factors or blood vessel recruitment. Many of these novel drugs can be used in combination with older, standard treatments to provide an enhanced, synergistic effect. Thus, novel and unique...

Tumor-growth suppressant for anti-cancer therapy

1616 — Human chorionic gonadotropin (hCG) plays an important role in cellular differentiation and proliferation. hCG and its subunits are secreted by many cancers including choriocarcinoma, germ cell tumors, hydatidiform moles , teratomas and islet cell tumors. Meanwhile the hCG-associated tumors may be stimulated by secreted hCG and proliferate in a feedback mechanism. Currently, there is no consensus for the best therapy for hCG-responsive tumors. There is certainly a need for a more effectiv...

Colon cancer inflammatory bowel disease patients

1640 — “Lead Inventors: lrena Kirman, MD, Ph.D. and Richard L. Whelan, MD Colon cancer risk and diagnosis for patients with inflammatory bowel disease: The invention provides a body fluid-based approach to diagnose, in a population of patients with inflammatory bowel disease (IBD), an individual's risk of developing colon cancer. IBD is a chronic inflammatory condition of the digestive tract, and the classification of IBD includes patients with ulcerative colitis and Crohn's Disease. 1 milli...

Tumor suppression and anti-cancer therapy

1694 — The p53 signaling pathway is a major potential target for anti-cancer therapies. Mutations in p53 are found in more than half of human cancers. Mutations in the p53 activating protein ARF have been documented in tumors where p53 was not mutated. To develop drugs that target p53 and ARF-mediated p53 activation, proteins that regulate p53 via ARF need to be identified and compounds that enable manipulating their activity need to be discovered. The present invention identifies ARF-BP...

Targeted cancer cell killing with caspase

m05-079 — While proper cellular apoptosis (cell death) is absolutely critical in the prevention of many forms of cancer, control and manipulation of this ubiquitous apoptotic pathway as a developing therapeutic strategy in cancer patients is hampered by leaky, non-specific, and potentially toxic side-effects. This invention offers a tightly controlled method to induce apoptosis in specific cells at a specific time by generating an active caspase (a key apoptotic-inducing protein) only when ...

Ovarian Cancer Therapy Human Follicle Hormone Antagonists

2232 — Survival rates for women diagnosed with ovarian cancer are very poor. With most patients diagnosed after the tumor has metastasized, non-responsiveness to chemotherapy further confounds treatment. There is a major need for therapeutic agents that specifically inhibit growth of ovarian tumors. The present invention comprises of recombinant human follicle stimulating hormone antagonist (rFSH-Ant) in which one or more N-glycosylation sites is disrupted. rFSH-Ant binds to the FSH rece...

Synergistic anti-cancer compound, panayxtriol and analogs

m08-089 — Toxicity and Side Effects of Chemotherapeutic Treatments The technology described here includes methods for treating cancer or neurotrophic disorders by administering a tubulin-binding drug in combination with panaxytriol or novel derivatives of panaxytriol. Panaxytriol may be produced either synthetically or from natural sources. The invention also includes methods for synthesizing of novel and more potent synthetic derivatives of panaxytriol. Patent pending (WO/200...

Cancer treatment for Tumor Cells Using RSL3

m10-018 — Drug candidate for cancer treatment is selective for cancer cells Patent Pending (US 61/274,949 & WO/2008/103470) ~ see link below. Available for Licensing and Sponsored Research Support STV Reference: IR M10-018 & M06-044

Metabolite Biomarker to Regulate Cancer Cell Growth

m10-032 — Cancer cells differ from most adult cells in their high uptake of glucose. The glucose is subsequently converted into lactate even in the presence of oxygen, allowing cells to accumulate glycolytic intermediates for cell biosynthetic processes. A key enzyme in the glycolytic pathway, pyruvate kinase M, has been implicated in determining the metabolic phenotype of cancer cells as opposed to normal adult cells. Pyruvate kinase M mRNA is alternatively spliced to produce two isoforms of the ...

Mouse for prostate cancer drug development

2668 — Prostate cancer is the second leading cause of cancer death in men. Although various therapeutic modalities exist currently (surgical, anti-hormone therapy, etc.) for prostate cancer, malignant and aggressive types of this disease remain refractory to current standard practices. Indeed, current research and development has focused on the formulation of new classes of drugs/compounds that may help improve survival. Animal models of prostate cancer are essential and needed for pre-clinical...

"Histone Acetyltransferase (HAT) Activators in Cancer Treatment "

2693 — Epigenetic modifications, particularly those affecting histone acetylation, have been implicated in a number of diseases, chief among them cancer. Addition of acetyl groups to histones by histone acetyltransferase (HAT) enhances gene expression while their removal by histone deacetylases (HDAC) reduces expression. Reduced histone acetylation has been linked to certain cancerous tumors. While there are a limited number of approved HDAC inhibitors, the activation of HAT, however, has not b...

Cervical Cancer Gene Markers for Targeted Therapy

2847 — Current treatment modalities for invasive cervical cancer result in largely unpredictable patient response. As a result, there is a pressing need for rational design of predictive biomarkers that can better guide treatment strategies in order to provide safer and more efficacious therapy. Recent advances in genomic and proteomic technologies have shown great promise in identifying biomarkers to enable more advanced diagnosis and allow for personalized therapy to improve clinical outcomes...

Compounds for targeted photodelivery of therapeutic substances for cancer

m09-102 — “Lead Inventors: , , Luis Baraldo, Ph.D. Tech Ventures Reference: M09-102 & In photodynamic therapy (PDT), light energy is used to induce a chemical reaction of a specifically-designed photosensitive drug. Using this method, the effects of the drug can be precisely targeted to the tissue of interest. Currently, PDT is used to treat Barrett's esophagus, and cancers of the esophagus, skin, lung, and pancreas. However, most PDT agents require high-energy ultraviolet light for effective...

Inducing Cancer Cell Death for Pancreatic Cancer with MDA-7/Anti-RAS Combination Therapy

1125 — Nucleic acid molecules encoding mda-7 or anti-RAS antisense molecules are transferred into cancer cells using viral vectors. The anti-RAS agent can also be a ribozyme, a precursor of a triple helix, or a farnesyl transferase inhibitor. MDA-7/Anti-RAS Combination Therapy for Identifying and Treating Pancreatic Cancer This technology shows that PAK5, a novel target of the Rho GTPases Cdc42 and Rac, triggers filopodia formation and neurite outgrowth in neuronal cell lines, a finding t...

Renal Cell Carcinoma Diagnostic

699 — The majority of kidney cancer deaths are caused by renal cell carcinoma (RCC). If RCC tumors are detected while still confined to the kidney, radical nephrectomy results in excellent long term survival. Unfortunately, symptoms of disease rarely occur prior to metastatic spread. Once RCC has metastasized, survival rates are less than 10% at five years. Until now, no suitable diagnostic marker existed for RCC detection, staging or for monitoring the effect of therapy. This invention provid...

Insulin-Like Growth Factor Protein 3 (IGF-BP3) for Inhibiting Tumor Growth

1266 — “Lead Inventors: lrena Kirman, MD, Ph.D. and Richard L. Whelan, MD Surgical Trauma Encourages Cancer Recurrence: This invention provides a method of preventing the proliferation of metastases and recurrence of cancer following open surgical resection of tumor mass. This is accomplished by monitoring and modulating the levels of the 43-45kD protein insulin-like growth factor binding protein-3 (IGFBP-3), the major insulin-like growth factor binding protein, in the patient's circulation. Fo...

Inhibitors of Human 9-cis Retinol Dehydrogenase Linked to Cancer Detection

740 — “Name of the inventor: William Blaner Cancer Detection Possible with Human Retinol Dehydrogenase: Methods of detecting compounds that are capable of inhibiting the enzymatic activity of human 9-cis retinol dehydrogenase in in-vitro and in-vivo conditions are described. The compounds capable of inhibiting human 9-cis retinol dehydrogenase include naturally occurring and synthetic retinoids and lipids. A method for detecting a predisposition to cancer or a disease associated with either a...

Melanoma Differentiation Associated Gene in Melanoma Cancer Cells

992 — Malignant melanoma is a serious type of skin cancer, due to uncontrolled growth of pigment cells. About 48,000 melanoma related deaths occur worldwide per year. Despite many years of intensive clinical research, the sole effective cure is surgical resection of the primary tumor before it achieves a thickness greater than 1mm. This technology exploited the defective differentiation process in melanoma cancer cells, constructed cDNA libraries from undifferentiated, actively prolifer...

Differentiation-Associated Sequences for Cancer Treatment and Vaccines

proxyfisher1 — “Name of the inventor: Fei Huang Cancer Diagnosis and Therapy with Isolated Polypeptide Compositions and methods for inhibiting cell growth, inducing terminal differentiation and cancer therapy are described. Polynucleotide Sequence Therapy for Inhibiting Cancer Development and Progression The isolated polypeptide comprises a portion of a differentiation-associated protein/a variant where the differentiation-associated protein comprises a sequence encoded by a polynucleotide sequence/a compl...

Transformation Progression-Related Genes for Cancer Diagnosis and Therapy

proxyfisher5 — “Name of the inventor: Paul Fisher Cancer Diagnosis, Monitoring and Therapy with Polypeptide Composition Compositions and methods for cancer diagnosis, monitoring and therapy are disclosed. The pharmaceutical composition comprises a polypeptide and a physiologically acceptable carrier. Cancer Progression Monitored and Inhibited with Isolated Polypeptide The isolated polypeptide comprises a portion of a progression-related protein/a variant wherein the progression-related protein retains at...

Heritable disorders, peripheral neuropathies, and cancer and neurodegenerative disorders screening

1562 — “Name of the inventor: Thomas M. Jessell Ph.D. In-vitro screening to identify drug targets for heritable disorders, peripheral neuropathies, and cancer and neurodegenerative disorders In-vitro systems for use in identifying modulators of neural differentiation and modulators identified by these systems are described. The method for identifying a modulator of neural differentiation comprises contacting the system with a candidate modulator and determining if the candidate modulator has ...

Cancer Therapy Target, Sir2Alpha-Mediated Regulation of P53 Function

1198 — The p53 tumor suppressor exerts anti-proliferative effects, including growth arrest, apoptosis and cell senescence in response to various types of stress. Inactivation of p53 functions has been well documented as a common mechanism for tumorigenesis. Many cancer therapy drugs have been designed based on either reactivating p53 functions or inactivating p53 negative regulators. But the precise mechanism by which p53 is activated is not completely understood, which limit the development of...

Discovery of RAS-selective drugs to treat cancer

m06-044 — Many anti-cancer drugs currently in use are toxic compounds that cause significant side effects. These agents are often not particularly selective for tumor cells and can cause unwanted damage or death to normal cells. Furthermore, the high doses required to maintain the efficacy of many anti-cancer drugs results in increased toxicity in patients. Drug resistance is also an issue for cancer therapies: high doses and repeated treatments can produce tumors that are resistant to available c...

Vaccine Therapy for Cancer Tumors using Antitumor Antibodies and ONTAK

1922 — Many antibody vaccines fail to induce active immunity despite binding the proper target and activating an immune response. Development of anti-tumor and anti-pathogen antibody vaccines is inhibited by the inability of antibody bound antigen to recruit antigen-presenting cells (APCs) and convert the response into active immunity. T regulatory (Treg) cells in addition to down-regulating the immune response also inhibit the conversion to active immunity. Combining the administration of anti...

Methods for Diagnosing and Treating Pediatric Neoplasm Cancer

1917 — The mortality from pediatric cancers can be reduced if tumors are diagnosed and treated at an early stage. Moreover, current treatment protocols can be invasive (surgery) or can produce deleterious side-effects. Side-effects are a particular concern in pediatric neoplasms because chemotherapy and radiation can interfere with growth and thus generate serious consequences. It is clear that alternative strategies for diagnosis and treatment of pediatric neoplasms are needed in order to achi...

Prostate Cancer Diagnostic, Prognostic and Therapeutic Tool using RAD9 Gene

2081 — Prostate cancer is the second most prevalent cancer type in American men and is now the second leading cause of cancer death within this group. Currently, there are a number of treatment options available, including surgery, radiation, chemotherapy, hormone therapy, and alternative approaches. Selecting one of these options often hinges on a number of factors including age, overall health, cancer grade, tumor localization/metastasis, and potential side effects. A cure for prostate cancer...

Cancer Therapeutics Targeting Oncogenic-RAS- Expressing Tumor Cells

m07-048 — Many anti-cancer drugs currently on the market come with significant side effects for patients because they are often not particularly selective for tumor cells, and can cause unwanted damage or death to normal cells. As a result, molecular targeted cancer therapeutics directed at specific oncogenic proteins or pathways represent a promising approach to cancer drug discovery. However, not all oncogenic proteins can be readily inhibited by a small molecule drug. For instance, the RAS onco...

Compositions for Synergistic Anti-Cancer Compound, Panayxtriol and Analogs

m07-065 — Anti-Cancer Drugs Increase Occurrences of Side Effects The technology described here includes methods for treating cancer or neurotrophic disorders by administering a tubulin-binding drug in combination with panaxytriol or novel derivatives of panaxytriol. Panaxytriol may be produced either synthetically or from natural sources. The invention also includes methods for synthesizing of novel and more potent synthetic derivatives of panaxytriol. Patent pending (WO/2008/...

Non-antibody cancer therapy with a tumor suppressor gene

2491 — According to the American Cancer Society, the incidence of cancer and the deaths due to cancer remain high. In 2010, over 500,000 Americans might die of cancer and nearly 1.5 million new cancer cases are expected to be diagnosed. As the incidence of cancer continues to rise, cancer therapies are needed more than ever. Conventional chemotherapy is limited by far reaching negative side effects due to the drug’s systemic toxicity that the patient may not be able to tolerate. Therefore, enti...

Novel Kinase Inhibitor Identified to Treat Tumor Progression in Cancer

2549 — Cancer is the second leading cause of mortality in the United States and continues to grow as a major health concern in the developing world. A distinguishing hallmark of cancer is the uncontrollable proliferation and growth of malignant tumor cells. Tumor progression is known to implement complex pathophysiological processes including activation of oncogenes, signaling diverse molecular pathways and angiogenesis, all of which contribute towards the advancement of the cancer. Despite exi...

"Mouse for luminal stem cells in prostate cancer"

2624 — “Lead Inventors: ; Mouse for prostate cancer diagnosis and risk detection using stem cells: Prostate cancer is one of the most common types of cancer in men. Prostate cancer occurs when cells within the prostate grow uncontrollably, creating small tumors. However, the lineage relationship between normal progenitor cells and cell type(s) of origin for cancer has been poorly understood, which hinders further therapeutic and prognosis development. Adult stem cells are of considerable biolog...

"Non-antibody cancer therapy using tumor suppressor gene "

2708 — According to the American Cancer Society, the incidence of cancer and the deaths due to cancer remain high. In 2010, over 500,000 Americans might die of cancer and nearly 1.5 million new cancer cases are expected to be diagnosed. As the incidence of cancer continues to rise, cancer therapies are needed more than ever. Conventional chemotherapy is limited by far reaching negative side effects due to the drug’s systemic toxicity that the patient may not be able to tolerate. Therefore, enti...

"Kidney cancer rapid drug screening using embryonic renal cell culture "

2696 — Cancer is one of the leading causes of death in the United States, and remains a field in which there is significant unmet need for therapeutic options. Current drug discovery models use various screening methods to identify potential therapeutic compounds by testing their level of activity against animal models of disease. Unfortunately, animal models of cancer require significant time and resources to produce, thus presenting a major barrier towards efficient screening of compounds. In...

Human Antibodies for Immuno-Histochemical Analysis of Prostate Cancer

2739 — Prostate cancer is the most common cancer in men after skin cancer. Early detection of cancers is key to successful treatment. Thus there is a need for improved detection methods. Nkx3.1 is involved cancer initiation, making it a useful marker for the detection and characterization of carcinomas. This technology provides new polyclonal antibodies for immuno-histochemical analysis of prostate carcinoma tissues. Nkx3.1 homeobox gene has restricted expression in the prostate and an e...

Mouse Antibodies for Immuno-Histochemical Analysis of Prostate Cancer

2738 — Prostate cancer is the most common cancer in men after skin cancer. Early detection of cancers is key to successful treatment. Thus there is a need for improved detection methods. Nkx3.1 is involved cancer initiation, making it a useful marker for the detection and characterization of carcinomas. This technology provides new polyclonal antibodies for immuno-histochemical analysis of prostate carcinoma tissues. The Nkx3.1 homeobox gene has restricted expression in the prostate and ...

Cancer Treatment with Statin-Like Drug for Mutant p53 Tumors

m11-022 — Over 50 percent of human tumors contain mutations in the gene encoding p53, a protein thought to play a role in early carcinogenesis. Classically, this gene is thought to be a tumor suppressor that causes cancer through a loss of function. However, mutant p53 has recently been shown to exhibit gain-of-function properties as well, causing cancer formation by enabling normally suppressed pathways. One such oncogenic pathway activated by this mutation is the sterol biosynthesis pathway. Inhibit...

CONEXIC Algorithmic Software: Tracking the Genetic Footprints of Cancer

m11-079 — Systematic characterization of cancer genomes has revealed a staggering number of diverse aberrations that differ among individuals, such that the functional importance and physiological impact of most tumor genetic alterations remain poorly defined. Multiple new genes have been implicated in cancer through several existing techniques, but the most significant lesson from these studies is that each tumor is unique and typically harbors a large number of genetic lesions, of which only a f...

Diffuse Optical Tomography Probe for Breast Cancer Imaging

cu12094 — Breast cancer affects approximately 1 in 8 women in the United States and the incidence of breast cancer throughout the world is increasing. With more than 200 000 new cases every year, it accounts for 28% of all new cancers diagnosed in women. Because of growing awareness, more women today are undergoing breast cancer screening, such as x-ray mammography. However, there have been noted cases of poorly maintained mammography machines emitting excessive x-ray radiation that can lead to ca...

Wireless Handheld Optical Probe for Breast Cancer Imaging

cu12093 — Breast cancer affects approximately 1 in 8 women in the United States and the incidence of breast cancer throughout the world is increasing. With more than 200 000 new cases every year, it accounts for 28% of all new cancers diagnosed in women. Because of growing awareness, more women today are undergoing breast cancer screening, such as x-ray mammography. However, there have been noted cases of poorly maintained mammography machines emitting excessive x-ray radiation that can lead to ca...

A TFF2-based peptide for treatment and prophylaxis of cancer

cu12276 — Trefoil factor family (TFF) proteins are primarily found in the epithelia of gastrointestinal tract and are upregulated in response to epithelial damage. TFF2 knockout studies in mice yield significant pathologies, highlighting this proteins role as an important anti-inflammatory mucosal defense mechanism. As inflammation in the gut is closely linked to cancer, TFF2 represents an attractive candidate for development as an anti-cancer prophylactic. Additionally, TFF2 demonstrates many tum...